Earnings History Data for Celldex Therapeutics, Inc. (CLDX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Celldex Therapeutics, Inc.

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
08-08-2024	AH		CLDX	Celldex Therapeutics	2,209	-0.54	-0.59	0.00	Celldex GAAP EPS of -$0.54 beats by $0.05, revenue of $2.49M beats by $1.64M [8/8/2024 5:49 PM]	32.83	0.12 (0.37%)	32.71	0.0 (0.00%)	22.11 - 53.18	265,249	930,000	16,292
Celldex GAAP EPS of -$0.54 beats by $0.05, revenue of $2.49M beats by $1.64M [8/8/2024 5:49 PM]
06-05-2024	AH		CLDX	Celldex Therapeutics	2,284	-0.56	-0.67	0.00	Celldex GAAP EPS of -$0.56, revenue of $0.16M [5/6/2024 4:41 PM]	42.34	0.69 (1.64%)	43.24	1.59 (3.82%)	22.11 - 53.18	716,819	580,000	305
Celldex GAAP EPS of -$0.56, revenue of $0.16M [5/6/2024 4:41 PM]
26-02-2024	PM		CLDX	Celldex Therapeutics	1,770	-0.57	-0.76	0.00	Celldex GAAP EPS of -$0.83 misses by $0.09, revenue of $4.13M beats by $3.27M [2/26/2024 7:10 AM]	48.09	10.34 (27.39%)	39.12	1.37 (3.63%)	22.11 - 48.96	4,340,542	730,000	31,258
Celldex GAAP EPS of -$0.83 misses by $0.09, revenue of $4.13M beats by $3.27M [2/26/2024 7:10 AM]
02-11-2023	AH		CLDX	Celldex Therapeutics	1,112	-0.81	-0.67	0.00	Celldex GAAP EPS of -$0.81 misses by $0.13, revenue of $1.51M beats by $0.93M [11/2/2023 5:22 PM]	25.95	1.94 (8.08%)	24.99	0.98 (4.08%)	22.11 - 48.40	1,021,307	450,000	34,023
Celldex GAAP EPS of -$0.81 misses by $0.13, revenue of $1.51M beats by $0.93M [11/2/2023 5:22 PM]
08-08-2023	AH		CLDX	Celldex Therapeutics	1,590	-0.65	-0.65	0.00	Celldex GAAP EPS of -$0.65 beats by $0.02, revenue of $0.27M misses by $0.39M [8/8/2023 5:15 PM]	30.42	-1.99 (-6.14%)	29.00	-3.41 (-10.52%)	27.01 - 48.40	780,636	310,000	11,074
Celldex GAAP EPS of -$0.65 beats by $0.02, revenue of $0.27M misses by $0.39M [8/8/2023 5:15 PM]
08-08-2022	AH		CLDX	Celldex Therapeutics	1,608	-0.58	-0.43	0.00	Celldex Non-GAAP EPS of -$0.59 misses by $0.17, revenue of $0.16M misses by $0.24M [8/8/2022 5:44 PM]	35.31	-2.16 (-5.76%)	35.87	-1.60 (-4.27%)	19.85 - 57.20	430,022	540,000	32,998
Celldex Non-GAAP EPS of -$0.59 misses by $0.17, revenue of $0.16M misses by $0.24M [8/8/2022 5:44 PM] Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update [Aug-08-22 04:01PM]
28-02-2022	AH	4:00 PM ET (Feb 28)	CLDX	Celldex Therapeutics, Inc.	1,400	-0.43	-0.42	-0.26	Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M [2/28/2022 4:02 PM]	31.54	1.64 (5.48%)	29.90	0.0 (0.00%)	15.37 - 57.20	791,046	530,000	6,175
Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M [2/28/2022 4:02 PM] Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update [Feb-28-22 04:01PM]
09-11-2021	AH		CLDX	Celldex Therapeutics	2,132	-0.39	-0.35	0.00	Celldex EPS misses by $0.09, misses on revenue [11/9/2021 4:51 PM]	45.83	-0.08 (-0.17%)	45.00	-0.91 (-1.98%)	15.37 - 57.20	219,772	350,000	126
Celldex EPS misses by $0.09, misses on revenue [11/9/2021 4:51 PM] Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update [Nov-09-21 04:01PM] Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates [Nov-09-21 06:15PM]
06-05-2021	AH		CLDX	Celldex Therapeutics, Inc.	1,200	-0.42	-0.32	-0.73	Celldex EPS misses by $0.08, misses on revenue [5/6/2021 5:03 PM]	27.28	0.71 (2.67%)	27.50	0.93 (3.50%)	2.20 - 33.23	490,505	500,000	268
Celldex EPS misses by $0.08, misses on revenue [5/6/2021 5:03 PM] Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates [May-06-21 06:35PM] Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update [May-06-21 04:01PM] Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates [May-06-21 06:35PM] Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update [May-06-21 04:01PM]
29-03-2021	AH	4:00 PM ET (Mar 29)	CLDX	Celldex Therapeutics, Inc.	1,028	-0.26	-0.37	0.00	Celldex EPS misses by $0.18, beats on revenue [3/29/2021 4:07 PM]	19.85	-0.62 (-3.03%)	19.05	-1.42 (-6.94%)	1.56 - 30.17	1,508,163	1,400,000	2,705
Celldex EPS misses by $0.18, beats on revenue [3/29/2021 4:07 PM] Celldex reports 80% complete response rate in CDX-0159 study in skin allergy [3/29/2021 7:06 AM] Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results [Mar-29-21 04:01PM] Why Is It Moving? Looking Into Why Celldex Therapeutics's Stock is Trading Lower Today [Mar-29-21 12:28PM] Why Celldex Therapeutics Stock Is Tanking Today [Mar-29-21 12:06PM] Celldex's CDX-0159 Shows 80% Response Rate In Early-Stage Skin Allergy Study [Mar-29-21 07:35AM] Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria [Mar-29-21 06:30AM]
06-08-2020	AH	4:00 PM ET (Aug 6)	CLDX	Celldex Therapeutics, Inc.	430.99	-0.57	-0.77	-0.84	Celldex EPS beats by $0.08, misses on revenue [8/6/2020 4:02 PM]	11.70	-0.01 (-0.09%)	11.32	-0.39 (-3.33%)	1.50 - 13.91	339,762	598,635	1,353